Conditions: Type 2 Diabetes Obesity
Keywords: doxycycline insulin resistance obesity inflammation
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 39
Healthy volunteers: yes

Brief summary:
Obesity is a heightened state of inflammation in which production of cytokines and matrix metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance insulin sensitivity and decreases inflammation in obese participants with type 2 diabetes (DM2).

Detailed description:
Design and Setting: 84 day (D84), double-blind, randomized, placebo (PL)-controlled clinical trial conducted in an academic tertiary care center.

Patients: Non-DM2 Controls (n=15); participants with DM2 receiving PL (n=13) or DOX (n=11).

Interventions: All participants were evaluated at day 1 (D1); those with DM2 were also evaluated at D84 after DOX 100mg twice daily or PL.

Arms:
arm 1: Participants with DM2 receiving doxycycline 100mg BID arm 2: Pills prepared identical to doxycycline.

Interventions: intervention 1: Doxycycline intervention 2: Placebo
Intervention descriptions: intervention 1: generic doxycycline 100mg twice daily intervention 2: Placebo comparator to doxycycline

Protocol document: